By conducting a phase I clinical study, Odunsi et al.65found that the use of DAC‐enhanced NY‐ESO‐1 vaccine to treat recurrent ovarian cancer can induce NY‐ESO‐1‐specific CD4+ and CD8+ T cell responses for up to 12 months. Here, CD8A is linked to ovarian carcinoma.